Skip to main content

Innoviva Inc(INVA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low21.63
Day High22.25
Open:22.22
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Innoviva Inc

Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Cybin (HELP), Twist Bioscience (TWST) and Innoviva (INVA)
Tipranks
Innoviva (INVA) Gets a Buy from Cantor Fitzgerald
Tipranks
Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)
MarketBeat
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
MarketBeat.com
Tipranks
Cantor Fitzgerald Sticks to Their Buy Rating for Innoviva (INVA)
Tipranks
Cantor Fitzgerald Keeps Their Buy Rating on Innoviva (INVA)
Business Wire
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
Business Wire
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
Business Wire
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
Business Wire
Innoviva to Participate in Upcoming Investor Conferences
Business Wire
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
Tipranks
Innoviva Reports Strong Q2 2025 Financial Results
Motley Fool
Innoviva (INVA) Q2 Sales Jump 64%
Business Wire
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
Tipranks
Analysts Conflicted on These Healthcare Names: EyePoint Pharmaceuticals (EYPT), Charles River Labs (CRL) and Innoviva (INVA)
Barchart
Chart of the Day: Innoviva - Individual Investor Favorite
INVA
PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR Newswire
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Business Wire
Innoviva Announces Retirement of Board Chairman
Barchart
Markets Today: Stock Index Futures Climb as China’s Economy Strengthens
Charts, tickers, traders - shutterstock_1033516756
Business Wire
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
Business Wire
Innoviva Stock Trading Halted Today
Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
PR Newswire
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
MarketBeat
Four Undervalued Healthcare Stocks for 2023
Business Wire
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Business Wire
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
Business Wire
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Business Wire
Innoviva Completes Acquisition of La Jolla Pharmaceutical
Business Wire
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Profile

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.